CA1341523C - Cloned dna sequences, hybridizable with genomic rna of lymphadenopathy-associated virus (lav) - Google Patents

Cloned dna sequences, hybridizable with genomic rna of lymphadenopathy-associated virus (lav) Download PDF

Info

Publication number
CA1341523C
CA1341523C CA000491128A CA491128A CA1341523C CA 1341523 C CA1341523 C CA 1341523C CA 000491128 A CA000491128 A CA 000491128A CA 491128 A CA491128 A CA 491128A CA 1341523 C CA1341523 C CA 1341523C
Authority
CA
Canada
Prior art keywords
dna
lav
bgl
hind iii
kpn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000491128A
Other languages
French (fr)
Inventor
Marc Alizon
Francoise Barre
Pierre Sonigo
Pierre Tiollais
Jean-Claude Chermann
Luc Montagnier
Simon Wain-Hobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur de Lille filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA000491128A priority Critical patent/CA1341523C/en
Application granted granted Critical
Publication of CA1341523C publication Critical patent/CA1341523C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to cloned DNAs which contains a DNA fragment hybridizable with the genomic RNA
of LAV viruses. They are useful as probes for the in vitro detection of viral infection in biological samples taken from persons possibly afflicted with AIDS.

Description

Cloned DNA sequences, hybridizable with crenomic RNA of lvmphadenopathv-associated virus (LAV) The invention relates to cloned DNA sequences hybridizable to genomic RNA and DNA of lymphadenopathy-associated virus (LAV), a process for their preparation and their uses. It relates more particularly to stable probes including a DNA sequence which can be used for the detection of the LAV virus or related viruses or DNA pro-viruses in any medium, particularly biological, samples containing of any them.
Lymphadenopathy-associated virus (LAV) is a human 15' retrovirus first isolated from the lymph node of a homo-sexual patient with lymphadenopathy syndrome, frequently a prodrome or a benign form of acquired immune deficiency syndrome (AIDS) (cf.1). Subsequently other LAV isolates have been recovered from patients with AIDS or pre-AIDS
(cf. 2-5). All available data are consistent with the virus being the causative agent of AIDS (cf. 11).
The virus is propagated on activated T lymphocytes and has a tropism for the T-cell subset OKT4 (cf. 2-6), in which it induces a cytopathic effect. However, it has been adapted for growth in some Epstein-Barr virus trans-formed B-cell lines (cf. 7), as well as in the established T-lymphoblastic cell line, CEM.
LAV-like viruses have more recently been indepen-dently isolated from patients with AIDS and pre-AIDS.
These viruses called HTLV-III (Human T-cell Leukemia/
Lymphoma virus type III (cf. 12-15) and ARV (AIDS-associated retrovirus) have many characteristics similar to those of LAV and they represent independent isolates of the LAV prototype. For the convenience of language they will hereafter all be referred to as "LAV".
Detection methods so far available are based on ~ .~ 4 J
the recognition of viral proteins. Such a method is disclosed in European application titled "Antig6nes, moyens et methode pour le diagnostic de lymphadenopathie et du syndrome d'immunodLpression acquise" filed on September 14, 1984 under the priority of British application Serial Nr. 83 24800 filed on September 15, 1983. As a matter of fact, a high prevalence of antibodies directed against the core protein having a molecular weight of about 25000 (p25) of the LAV
retrovirus, has been found in the sera of AIDS and pre-AIDS
patients and to a lower but significant extent in the high-risk groups for AIDS (cf. 8-10).
The present invention aims at providing new means which should not only also be useful for the detection of LAV or related viruses (hereafter more generally referred to as "LAV viruses"), but also have more versatility, particularly in detecting specific parts of the genomic DNA
of said viruses whose expression products are not always detectable by immunological methods.

~

~3 4 1 5 2~
2a The present invention relates to a DNA
molecule which contains a cDNA sequence of a LAV
virus sequence shown in Figures 4 to 11 or a cDNA
sequence that is complemetary to the sequence shown in Figures 4 to 11 or a fragment of cDNA sequence, wherein the fragment is characterized by at least one of the following restriction sites:

Restriction Site Nucleotide position Hind III 0 Sac I 50 Bam HI 460 Hind III 520 Bam HI 600 Pst I 800 Hind III 1,100 Bgl II 1,500 Kpn I 3,500 Kpn I 3,900 Eco RI 4,100 Eco RI 5,300 Sal I 5,500 Kpn I 6,100 Bgl II 6,500 Bgl II 7,600 Hind III 7,850 Barrm HI 8,150 Xho I 8,600 Kpn I 8,700 Bgl I 8,750 Bgl II 9,150 Sac I 9,200 Hind III 9,250.
-~rol 13 415 2~
2b The present invention also relates to a probe for the in vitro detection of LAV which consists of a nucleotide sequence that hybridizes to the sequence shown in Figures 4 to 11 under conditions of high stringency or a nucleotide sequence that hybridizes to a fragment under conditions of high stringency, wherein the fragment is characterized by at least one of the following restriction sites :

Restriction Site Nucleotide position Hind III 0 Sac I 50 Bam HI 460 Hind III 520 Bam HI 600 Pst I 800 Hind III 1,100 Bgl II 1,500 Kpn I 3,500 Kpn I 3,900 Eco RI 4,100 Eco RI 5,300 Sal I 5,500 Kpn I 6,100 Bgl II 6,500 Bgl II 7,600 Hind III 7,850 Bam HI 8,150 Xho I 8,600 Kpn I 8,700 Bgl I 8,750 Bgl II 9,150 ,~

13 ~~~215~
2c Sac I 9,200 Hind III 9,250.

The present invention also relates to a method for the in vitro detection of a viral infection due to LAV viruses which comprises contacting a biological sample originating from a person to be diagnosed for LAV infection and containing DNA in a form suitable for hybridization with a probe specific for LAV DNA under highly stringent hybridizing conditions and detecting the hybridized probe.

The present invention also relates to a recombinant expression vector for the transformation of prokaryotic or eukaryotic cells, which contains, inserted in an expression vector, a DNA or a DNA
fragment as defined above.

The present invention also relates to a microorganism, eukaryotic or prokaryotic cell, which is transformed by a recombinant expression vector as defined above and which expresses the polypeptide encoded by the corresponding DNA fragment.

The present invention also relates to a polypeptide encoded by the DNA as described above and expressed by the microorganisms as described above.

The present invention also relates to a purified RNA of LAV viruses which has sizes from 9.1 to 9.2 kb and which hybridizes with the DNA molecule as defined above under high stringency conditions.

The present invention also relates to a RNA comprising LAV nucleotidic sequences and obtainable by transcription of or back synthesis 13 415-2~
2d from a cloned DNA which contains a DNA insertion fragment being all or part of a cDNA of a LAV
retroviral genome contained in lambdaJl9 (CNCM I-338) of LAV, wherein the DNA hybridizes under non stringent conditions with the genomic RNA of the LAV
virus, but does not cross-hybridize with RNAs of HTLV-I and HTLV-II retroviruses in a dot-blot hybridization assay under low stringency conditions.

The present invention also relates to a DNA in which a DNA insert comprises a sequence extending from KpnI (6,100) to PvuII (8,500).
The present invention also relates to a kit for detecting LAV comprising a biological sample containing the RNA as described above.

The present invention also relates to a kit for detecting LAV comprising an RNA as described above.

The present invention also relates to a DNA in which a DNA insert comprises a sequence extending from KpnI (3,500) to PvuII (6,500).

The present invention also relates to a DNA in which a DNA insert comprises a sequence extending from PstI (800) to PvuII (3,800).

The present invention also relates to a DNA which contains a DNA insert being a LAV
retroviral genome contained in kJ19 (C.N.C.M.
I-338) .
The present invention also relates to a DNA hybridizing under stringent conditions to the DNA insert as defined above.

,~

2e Reference is hereafter made to the drawings in which:
- fig. 1 shows restriction maps of preferred cDNA inserts contained in plasmid recombinants, wherein said cDNA
inserts consist of cDNA fragments corresponding to RNA
fragments of the LAV retroviral genome;
- fig. 2 shows restriction maps of cDNA fragments derived from corresponding genomic retroviral fragments including the full retroviral genome of LAV;
- fig. 3 is a restriction map of cDNA corresponding to a complete LAV genome (clone IJ19);
- fig. 4 to 11 show the whole sequence of the LAV genoma, the restriction map of which is shown in fig. 3.
The DNAs according to the invention contain DNA
fragments hybridizable with the genomic RNA of LAV.
Particularly any of said DNA fragments consist of a double-stranded DNA resulting from the cloning of an initial fragment obtained as a result of transcription of a corresponding RNA fragment of the.LAV retroviral genome into the first strand of said double-stranded DNA whose second strand was transformed starting from the relevant nucleotide in the presence of a polymerase. The DNA
according to the invention include recombinant DNAs containing said cDNAs or cDNA fragments.
Preferred clones cDNA fragments respectively contain the following restriction sites in the respective orders which follow (from the 3' end to the 5' end):
1) HindIII, SacI, BglII (LAV75) 2) HindIII, SacI, BglII, BglIII, KpnI (LAV82) ~....~
3) HindIII, Sacl, BglII, BglII, KpnI, XhoI, BamHI, HindIII, Bg11I (LAV13).
The LAV75, LAV82 and LAV13 designations correspond to the designations of the recombinant plasmids designated as pLAV 75, pLAV 82 and pLAV 13 respectively, in which they were first cloned. In other words LAV 75, LAV 82 and LAV 13 respectively present as inserts in said recombinant plasmids. For convenience the designations LAV 75, LAV 82 and LAV 13 will be further used throughout this specific-ation to designate the cDNA fragments, whether the latter are in isolated form or in a plasmid forms, whereby the other DNA parts of said last mentioned recombinants are identical to or different of the corresponding parts of pLAV 75, pLAV 82 and pLAV 13 respectively.
Preferred cDNAs also (like LAV 75, LAV 82 and LAV
13) contain a region corresponding to the R and U 3 re-gions of the LTR (Long Terminal Repeat) as well as the 3' end of the coding region of the retroviral DNA. Particu-larly if it is assumed that the retroviral structure of LAV is in general agreement with the retroviral genomic structures to date.
LAV 13 which has a size of about 2.5 Kbp has been found of particular advantage. It is highly specific of LAV or LAV related viruses and does also recognizes more of the LAV retroviral genomes than do LAV75 or LAV82.
Particularly LAV 13 enabled the identification of the RU 5 junction of the retroviral genomes within the LTR and, subsequently, the sizes of the LAV genomes, which average from about 9.1 to about 9.2 kb.
LAV 13 is free of restriction sites for the following enzymes Eco RI, Nru I, Pvu I, Sal I, Sma I, Sph I, Stu I and Xba I.
LAV 13 further appears to contain at least part of the DNA sequences corresponding to those which, in retroviral genomes, code for the envelope protein.
The invention further relates to any of the fragments contained in the cDNA which seems to correspond to part of the whole of the LAV retroviral genome, which is characterized by a series of restriction sites in the order hereafter (from the 5' end to the 3' end).
The coordinates of the successive sites of a preferred whole LAV genome (restriction map) are indicated hereafter too, with respect to the Hind III site (selected as of coordinate 1) which is located in the R region. The coordinates are estimated to within + 200 bp. Some coor-dinates are better established than others.
Hind III 0 Sac I 50 Bam HI 460 Hind III 520 Bam HI 600 Pst I 800 Hind III 1 100 Bgl II 1 500 Kpn I 3 500 Kpn I 3 900 Eco RI 4 100 Eco RI 5 300 Sal. I 5 500 Kpn I 6 100 Bgl II 6 500 Bgl II 7 600 Hind III 7 850 Bam HI 8 150 Xho I 8 600 Kpn I 8 700 Bgl II 8 750 Bgl II 9 150 Sac I 9 200 Hind III 9 250 The abovesaid DNA according to the invention optionally contains an additional Hind III approximately 4 1 b 2~
at the 5 550 coordinate.
More particularly the invention pertains to a DNA
having an approximate_ size of 9.1 kb and comprising the series of restriction sites referred to in fig. 3.
5 More generally the invention relates more parti-cularly to cDNA variants of the latter, which variants may possess the same series of restriction sites in the order hereafter (from the 5' end to the 3' end) yet with some of them being deleted or added owing to mutatins either induced willingly or not.
The invention further relates to other preferred DNA fragments corresponding substantially to those which in relation to the abovesaid restriction map extend res-pectively - from approximately Kpn I(6 100) to approximately Bgl II
(9150) said fragment being thought to correspond at least in part to the gene coding for the proteins of the envelope ; in particular a protein p110 of about 110,000 Daltons is encoded by this region ;
- from approximately Kpn I(3 500) to approximately Bgl II
(6500), said fragment being thought to correspond at least in part to the pol gene, coding for the virus polymerase - from approximately Pst (800) to approximately Kpn I
(3500), said fragment being thought to correspond at least in part to the gag gene, which codes for the core anti-gens, including the p25, the p18, and the p13 proteins.
The invention also relates to additional DNA frag-ments, hybridizable with the genomic RNA of LAV as they will be disclosed hereafter, as well as with additional cDNA variants corresponding to the whole genomes of LAV
viruses. It further relates to DNA recombinants containing said DNAs or cDNA fragments.
More particularly the invention relates to any fragment corresponding to the above ones, having subs-tantially the same sites at substantially same distances from one another, all of these fragments having in common the capability of hybridizing with the LAV retroviral genomes. It is of course understood that fragments which would include some deletions or mutations which would not substantially alter their capability of also hybridizing with the LAV retroviral genomes are to be considered as forming obvious equivalents of the DNA fragments more specifically referred to hereabove.
Additional features of the invention will appear in the course of the disclosure of additional features of preferred DNAs of the invention, including restriction maps and nucleotide sequences, the preparation conditions and the properties of which will be illustrated hereafter in a non limitative manner.
1. Construction of a cDNA library 1.1 Virus purification Virions were purified from FR8, an immortalized, permanent =LAV producing B-Lymphocyte line (cf. 7) (deposited at the "Collection Nationale de Cultures de Micro-organismes" of the INSTITUT PASTEUR of Paris, under Nr. 1-303 on May 9, 1984). The purification protocol was described (cf. 1). The main steps were polyethylene-glycol treatment of culture supernatant, pelleting through 20 : sucrose cushion, banding on 20-60 :
sucrose gradient and pelleting of the virus-containing fractions.
1.2 First-strand cDNA synthesis The virus associated detergent activated endoge-nous reaction is a technique bringing into play the reverse transcriptase of the virus, after purification thereof and lysis of its envelope.
For each reaction, purified virus corresponding to 250-300 ml of FR8 supernatant was used. Final reaction volume was 1 ml. Incubation was at 37'C for 45 mn. Protein concentration was about 250 microg/ml. Buffer was : NaCl 25 mM ; Tris HC1 pH 7.8 50 mM, dithiothreitol 10 mM, MgC12 6 mM, each of dATP, dGTP, dTTP at 0.1 mM, Triton X-100 7 _ 0.02 t ; oligo dT primer 50 microg/ml. The cDNA-RNA was labelled 15 mn with alpha 32p-dCTP 400 Ci/mmole to 0.6 microM plus cold dCTP to 4 microM. Afterwards, cold dCTP
was added to 25 microM to ensure optimal elongation of the first strand.
The reaction was stopped 30 mn after the dCTP
chase by adding EDTA to 20 mM, SDS to 0.5%, digesting one hour with proteinase K at 100 microg/ml and phenol-chloro-form extraction.
cDNA-RNA was then purified on G-50 Sephadex (Pharmacia) and ethanol precipitated.
1.3 2nd strand synthesis and cloning Purified cDNA-RNA hybrids were treated with DNA
polymerase I and RNase H, according to GUBLER and HOFFMAN
(cf. 17). Double-stranded cDNA was dC-tailed with terminal transferase and annealed to dG-tailed Pst-digested pBR 327 (cf. 34) a derivative of pBR 322.
A cDNA library was obtained by transfection of coli C 600 recBC strain.
2. Detection of LAV-svecific clones 2.1 Screening of the library 500 recombinant clones were grown on nitrocellu-lose filtres and in situ colony hybridization (cf. 35) was performed with another batch of cDNA made in endogenous virus-associated reaction as described (cf. 1.2) and labelled with 32P. About 10 % of the clones could be detected.
A major family was obtained by small-scale amplification of these clones and cross-hybridization of their inserts. Among these clones a major family of hybri-dizing recombinants was identified. Three of these cDNA
clones, named pLAV 13, 75 and 82, carrying inserts of 2.5, 0.6 and 0.8 kb respectively were further characterized (fig. 1).
All three inserts have a common restriction pattern at one end, indicating a common priming site. The 50 bp long common Hind III-Pst I fragment was sequenced (fig. 1) and shown to contain a polyA stretch preceeding the cloning dC tail. The clones are thus copies of the 3' end of a polyA-RNA.
The LAV 13 specificity was shown by different assays.
The specificity of pLAV 13 was determined in a series of filter hybridization experiments using nick-translated pLAV 13 as a probe. Firstly the probe hybri-dized to purified LAV genomic RNA by dot and Northern blotting (data not shown). pLAV 13 also hybridizes to the genomic RNA of virus concentrated from culture supernatant directly immobilized on filters (dot blot technique). LAV
RNA from different sources : normal T-cells, FR8 and other B-cell LAV producing lines, CEM cells and, although less strongly, LAV from the bone marrow culture from a haemo-philiac with AIDS (cf. 3) were detected in a similar manner. Uninfected cultures proved negative. This rapid dot blot technique can be adapted with minor modifications to the detection of LAV in serum or other body fluids.
Secondly the probe detected DNA in the Southern blots of LAV-infected T-lymphocytes and in the LAV-producing CEM cell line. No hybridization was detected in the DNA of uninfected lymphocytes nor in the DNA from normal liver (data not shown) under the same hybridization conditions.
A third characteristic resulted from the possibi-lity of using LAV 13 to identify the whole retroviral genome of the LAV viruses as disclosed hereafter. Parti-cularly characteristic 1.45 kb Hind III fragment which co-migrates with an internal viral fragment in Hind III
cleaved pLAV 13 was detected. Bands at 2.3 and 6.7 kb were also detected. As the probe was only 2.5 kb long and as no junction fragments could be detected, it is probable that these extra-bands represent internal fragments arising from a Hind III polymorphism of the LAV genome.
Together these data show that pLAV 13 DNA is exo-genous to the human genome and detects both RNA and inte-grated DNA forms derived from LAV infected cells. Thus pLAV 13 is LAV specific. Being oligo-dt primed, pLAV 13 must contain the R and U3 regions of the LTR as well as the 3' end of the coding region, assuming a conventional retroviral genome structure.
Cloning of LAV Qenomic DNA
Having found a HindIII site within the R region of the LTR, it was decided to clone the LAV genome by making a partial Hind III digest of proviral DNA from LAV
infected cells. It was found that :(a) partial digestion increased the chance of isolating complete clones and (b) Hind III fragments were easily cloned in lambda replace-ment vectors. The DNA isolated from T-cells of a healthy donor after i} vitro infection with LAV was partially digested with Hind III and fractionated. A 9*- 1.5 kb DNA
containing fraction was precipitated and ligated into the Hind III arms of lambda-L47.1 (cf. 18).
The cloning of LAV genomic DNA was carried out more particularly as follows :
cDNAs was prepared from LAV infected T cells as described above, then partially digested with Hind III and fractionated on a 5-40 % sucrose gradient in 10 mM Tris.Cl pH 8, 10 mM EDTA, 1 M NaC1 (SW41 rotor, 16 hours at 40 000 rpm). A single fraction (9 0.5 kb) was precipitated with 20 microg/ml Dextran T40 as carrier and taken up in TE-buffer (10 mM Tris.Cl pH 8, 1 mM EDTA). Lambda-L47.1 Hind III arms were prepared by frist ligating the cos sites followed by Hind III digestion and fractionation through a 5-40 % sucrose gradient. Fractions containing only the lambda-Hind III arms were pooled, precipitated and taken up in TE-buffer. Ligation of arms to DNA was made at approximately 200 microg DNA/ml using a 3:1 molar excess of arms and 300 units of T4 DNA ligase (Biolabs). ~}r vitro packaging lysates were made according to (38). After i}

vitro packaging the phage lysate was plated out on NM538 on a C600 recBC strain. Approximately two million plaques were screened by in situ hybridization (cf. 39) using ni-trocellulose filters. Hybridization was performed at 68'C
5 in 1 x Denhardt solution, 0.5 % SDS, 2 x SSC, 2 mM EDTA.
Probe : 32P nick-translated LAV insert of pLAV 13 at >108 cpm/microg Filters were washed 2 x 30 minutes in 0-1 SSC, 0.1 % SDS at 68'C, and exposed to Kodak XAR-5 film for 29-40 hours. Seven positive clones were identi-10 fied and plaque purified on a C 600 rec BC strain. Liquid cultures were grown and the recombinant phages banded in CsCl. Plage DNA was extracted and digested under the appropriate conditions.
Seven independent clones were so derived from approximatively two million phage plaques after screening in situ with a nick-translated pLAV 13 insert as a probe.
Restriction maps of lambda-J19 as well as of a Hind III
polymorph lambda-J81 are shown in fig. 2. Other recom-binants lambda-J27, lambda-J31 and lambda-J57 had the same Hind III map as lambda-J19. The map of lambda-J81 is identical but for an additional Hind III site at coordinate of approximately 5 550.
The restriction maps of fig. 2 were oriented by hybridizing blots with respect to pLAV 13 DNA.
The restriction map of the LAV 13 cDNA clone is also shown in fig. 2. The restriction sites of lambda-J19 are . B-Bam HI, Bg-Bgl II, H-Hind III, K-Kpn I, P-Pst I, R-Eco RI, S-Sac I, Sa-Sal-I and X-Xho I. Underneath the scale is a schema for the general structure of the retro-viruses showing the LTR elements U3, R and U5. Only the R/US boundary has been defined and other boundaries are only drawn figuratively.
There may be other Bam HI sites in the 5' 0.52 kb Hind III fragment of lambda-J19. They generate fragments 3.5 that are too small to be detected.
Fig. 2 also shows those Hind III fragments of lambda-J19 and lambda-J81 which are detected by pLAV 13 (marked (+)), those which are not detected (-).
More particularly lambda-J19 shows four Hind III
bands of 6.7, 1.45, 0.6 and 0.52 kb the first two of which correspond to bands in the genomic blot of Hind III res-tricted DNA. The smallest bands of 0,6 and 0,52 kb were not seen in the genomic blot but the fact that they appear in all the independently derived clones analyzed indicates that they represent internal and not junction fragments, assuming a random integration of LAV proviral DNA. Indeed, the 0,5 kb band hybridizes with pLAV 13 DNA (fig. 2) through the small Hind III-Pst I fragment of pLAV 13. Thus the 0,5 kb Hind III fragment of lambda-J19 contains the R-U5 jur.ction within the LTR.
It appears that lambda-J81 is a restriction site polymorph of lambda-J19. Lambda-J81 shows five Hind III
bands of 4.3, 2.3, 1.45, 0.6 and 0.52 kb. The 2.3 kb band is readily detected in the genomic blot by a pLAJ 13 probe, but not the 4.3 kb fragment. That lambda-J81 is a Hind III polymorph and not a recombinant virus is shown by the fact that nick-translated lambda-J19 DNA hybridizes to all five Hind III bands of lambda-J81 under stringent hy-bridization and washing conditions. Also other restric-tions sites in lambda-J81 are identical to those of lam-bda-J19.
Sequencing of the LAV-derived cDNA.
The sequencing and determination of sites of par-ticular interest was carried out on phage recombinant.
The whole recombinant phage DNA of clone XJ19 was sonicated according to the protocol of DEININGER (1983), Analytical Biochem. 129, 216. The DNA was repaired by a Klenow reaction for 12 hours at 16'C. The DNA was electrophoresed through 0.8 % agarose gel and DNA in the size range of 300-600 bp was cut out and electroeluted and precipitated. Resuspended DNA (in 10 mM Tris, pH 8 ; 0,1 mM EDTA) was ligated into M13mp8 RF DNA (cut by the 134152~
restriction enzyme SmaI and subsequently alkaline phosphated), using T4 DNA- and RNA-ligases (Maniatis T et al (1982) - Molecular cloning - Cold Spring Harbor Laboratory). An JE. co i strain designated as TG1 was used for further study. This strain has the following genotype:
Alac pro, supE, thi.F'traD36, proAB, IacIq, 2AM15,r This E. c.oli TGI strain has the peculiarity of enabling recombinants to be recognized easily. The blue colour of the cells transfected with plasmids which did not recombine with a fragment of LAV DNA is not modified.
To the contrary cells transfected by a recombinant plasmid containing a LAV DNA fragment yield white colonies. The technique which was used is disclosed in Gene (1983), 26, 101.
This strain was transformed with the ligation mix using the Hanahan method (Hanahan D (1983) J. Mol. Biol.
166,557). Cells were plated out on tryptone-agarose plate with isopropyl-B-D-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-B-D-galactopyranoside(X-gal) in soft agarose. White plaques were either picked and screened or screened directly in situ using nitrocellulose filters. Their DNAs were hybridized with nick-translated DNA inserts of pUC18 Hind III subclones of I which are identified in the table hereafter. In relation to this table, it should also be noted that the designation of each plasmid is followed by the deposition number of a cell culture of JE. coli TGI containing the corresponding plasmid at the "Collection Nationale des Cultures de Micro-organismes" (C.N.C.M.) of the Pasteur Institute in Paris, France. A non-transformed TGI cell line was also deposited at the C.N.C.M. under Nr. 1-364. All these deposits took place on November 15, 1984. The sizes of the corresponding inserts derived from the LAV genome have also been indicated.

. :1 TABLE
Essential features of the recombinant plasmids - pJ19 - 1 plasmid (1-365) 0.5 kb Hind III - Sac I - Hind III

- pJ19 - 17 plasmid (1-367) 0.6 kb Hind III - Pst 1- Hind III

- pJ19 - 6 plasmid (1-366) 1.5 kb Hind III (5') Bam HI
Xho I
Kpn I
Bgl II
Sac I (3') Hind III

- pJ19-13 plasmid (1-368) 6.7 kb Hind III (5') Bgl II
Kpn I
Kpn I
Eco RI
Eco RI
Sal I
Kpn I
Bgl II
Bgl II
Hind III (3') Positively hybridizing M13 phage plates were grown up for 5 hours and the single-stranded DNAs were 14 ~3 4 1 5 2 3 extracted.
M13mp8 subclones of AJ19 DNAs were sequenced according to the dideoxy method and technology devised by Sanger et al (Sanger et al (1977), Proc. Natl. Acad. Sci.
USA, 74 , 5463 and M13 cloning and sequencing handbook, AMERSHAM (1983). the 17-mer oligonucleotide primer a-35SdATP (400Ci/mmol, AMERSHAM), and 0.5X-5X buffer gradient gels (Biggen M.D. et al (1983, Proc. Natl. Acad.
Sci. USA, 50, 3963) were used. Gels were read and put into the computer under the programs of Staden (Staden R.
(1982), Nucl. Acids Res. 10. 4731). All the appropriate references and methods can be found in the AMERSHAM M13 cloning and sequencing handbook.
The complete sequence of AJ19 is shown in figs 5-12.
Relationship to other human retroviruses HTLV-I and HTLV-II constitute a pair of C-type transforming retroviruses with a tropism for the T-cell subset, OKT4 (cf. 20). An isolate of HTLV-I has been totally sequenced (cf. 21) and partial sequencing of an HTLV-II has been reported (cf. 22-24). Both genomes (one LTR) were approximately 8.3 kb in length, have a pX region and show extensive sequence homology. They hybridize between themselves under reasonably stringent conditions (40 % formamide, 5 XSSC) and even at 60 % formamide the pX
regions hybridize (cf. 26). Thus a conserved pX region is a hallmark of this class of virus.
We have compared cloned LAV DNA and cloned HTLV-II
DNA (pMO (cf. 27)) by blot-hybridization and found no cross-hybridization under low stringency conditions of hybridization and washing. For example, Hind III digested lambda-J19, lambda-J27 and lambda-J81 were electropho-resed, blotted and hybridized overnight with 32P
nick-translated pM0 (HTLV-II) DNA (having a specific activity greater than 0.5 X 108 cpm/microg) in 20 %
formamide, 5 XSSC, 1 X Denhardts solution, 10 % Dextran sulphate,at 37'C. Filters were washed at 37'C (tm.50) tm.50 using a 53.1 % GC content derived from the HTLV-I
sequence (21). The washings were repeated at 50'C and 65'C
in 1 x SSX, 0.1 % SDS. Even when hybridized in 20 %
5 formamide, 8 X SSC (tm.50) and washed at 37'C in 2 X SSC
(tm.50) no hybridization was detected after two days exposure at -70'C using an intensifying screen.
Thus there is no molecular evidence of a relation-ship between LAV and the HTLV viruses. In addition, the 10 LAV genome is approximately 9 kb long in contrast to 8.3 kb for the HTLV viruses. Despite their comparable genome sizes LAV and Visna (cf. 29) cloned viral genomes do not cross-hybridize, nor does LAV with a number of human endogenous viral genomes (cf.30) under non stringent 15 conditions (hybridization-20 -o formamide, 8 SSC, 37'C
washing - 2 SSC, 0.1 % SDS, 37 C.
The invention also relates more specifically to cloned probes which can be made starting from any DNA
fragment according to the invention, thus to recombinant DNAs containing such fragments, particularly any plasmids amplifiable in procaryotic or eucaryotic cells and carry-ing said fragments. As mentioned earlier a preferred DNA
fragment is LAV 13.
Using the cloned provirus DNA as a molecular hy-bridization probe - either by marking with radionucleo-tides or with fluorescent reagents - LAV virion RNA may be detected directly in the blood, body fluids and blood products (e.g. of the antihemophylic factors such as Factor VIII concentrates) and vaccines, i.e. hepatitis B
vaccineIt has alredy been shown that whole virus can be detected in culture supernatants of LAV producing cells. A
suitable method for achieving that detection comprises immobilizing virus onto said a support e.g. nitrocellulose filters, etc., disrupting the virion and hybridizing with labelled (radiolabelled or "cold" fluorescent- or enzyme-labelled) probes. Such an approach has already been developed for Hepatitis B virus in peripheral blood (according to SCOTTO J. et al. Hepatology (1983), 379-384).
Probes according to the invention can also be used for rapid screening of genomic DNA derived from the tissue of patients with LAV related symptoms, to see if the pro-viral DNA or RNA is present in host tissue and other tissues.
A method which can be used for such screening comprise the following steps : extraction of DNA from tis-sue, restriction enzyme cleavage of said DNA, electrophoresis of the fragments and S_outhern blotting of genomic DNA from tissues, subsequent hybridization with labelled cloned LAV
provival DNA. Hybridization in situ can also be used.
Lymphatic fluids and tissues and other non-lympha-tic tissues of humans, primates and other mammalian spe-cies can also be screened to see if other evolutionnary related retrovirus exist. The methods referred to here-above can be used, although hybridization and washings would be done under non stringent conditions.
The DNA according to the invention can be used also for achieving the expression of LAV viral antigens for diagnostic purposes as well as far the production of a vaccine against LAV. Of particular advantage in that res-pect are the DNA fragments coding core (gag region) and for envelope proteins, particularly the DNA fragment extending from Kpn I(6 100) to BglII(9 150).
The methods which can be used are multifold a) DNA can be transfected into mammalian cells with appropriate selection markers by a variety of tec-hniques, calcium phosphate precipitation, polyethylene glycol, protoplast-fusion, etc..
b) DNA fragments corresponding to genes can be cloned into expression vectors for E. coli , yeast- or mammalian cells and the resultant proteins purified.
c) The provival DNA can be "shot-gunned" (frag-mented) into procaryotic expression vectors to generate fusion polypeptides. Recombinant producing antigenically competent fusion proteins can be identified by simply screening the recombinants with antibodies against LAV
antigens .
d) The invention also relates to oligopeptides deduced from the DNA sequence of LAV antigen-genes to produce immunogens and antigens and which can be synthethised chemically.
All of the above (a-d) can be used in diagnostics as sources of immunogens or antigens free of viral par-ticles, produced using non-permissive systems, and thus of little or no biohazard risk.
The invention further relates to the hosts (proca-ryotic or eucaryotic cells) which are transformed by the above mentioned recombinants and which are capable of expressing said DNA fragments.
-Fina,lly it also relates to vaccine compositions whose active principle is to be constituted by any of the expressed antigens, i.e. whole antigens, fusion polypep-tides or oligopeptides.
The invention finally refers to the purified genomic mRNA, which can either be extracted as such from the LAV viruses or resynthesozed back from the cDNA, particularly to a purified mRNA having a size appro-ximating 9.1 to 9.2 kb, hybridizable to any of the DNA
fragments defined hereabove or to parts of said purified mRNA. The invention also relates to parts of said RNA. The nucleotidic structures of this purified RNA or of the parts thereof can indeed be deduced from the nucleotidic sequences of the related cDNAs.
It will finally be mentioned that lambda-J19 and lambda-J81 have been deposited at the Collection Natio-nale des Cultures de Micro-organismes (C.N.C.M.) of the INSTITUT PASTEUR of Pasteur (France) under Nr. 1-338 and 1-339 respectively, on September 11, 1984.
The invention finally refers to the genomic DNA, the DNA sequence of which can be determined and used to predict the aminoacid sequences of the viral protein (antigens) and to the RNA probes which can be derived from the cDNA.
There follows the bibliography to which references have been made throughout this specification by bracketted numbers.
REFERENCES
I Barre-Sinoussi, F. et al. Science 220, 868-871 (1983).

2 Montagnier, L. et al. in Human T-cell Leukemia Viruses (eds. R.C.
Gallo, M. Essex and L. Gross) p. 363-379 (Cold Spring Harbor, New-York, 1984).

3 Vilmer, E. et al. Lancet, ii, 753-757 (1984).

4 Ellrodt, A. et al. Lancet, 1, 1383-1385 (1984).
Feorino, M.P. et al. Science, 225, 69-72 (1984).
6 Klatzmann, D. et at. Science, 225, 59-63 (1984).
7 Montagnier, L. et al. Science, 885, 63-66 (1984).

8 Brun-Vezinet, F. et al. Lancet, i, 1253-1256 (1984).

9 Kalyanaraman, V.S. et al. Science, 225, 321-323 (1984).

11 Montagnier, L., Barre-Sinoussi, F. and Chermann, J.C. in Prog.
Immunodef. Res. Therapy, l, (eds. C. Griscelli and J. Vossen) p.367-372 (Excerpta Medica, Amsterdam, 1984).

12 Popovic, M., Sarngadharan, M.G., Read, E. and Gallo, R.C. Science, 224, 497-500 (1984).

13 Gallo, et al. Science, 224,500-503 (1984).

14 Schupbac,ti, J. et al. Science, 224, 503-505 (1984).

Sarngadharan, M.G., Popovic, M., Bruch, L., Sch0pbach, J. and Gallo, R.C. Science, 224, 506-508 (1984).

16 Levy, J.A. et al. Science, 225, 840-842 (1984).

17 Gubler, U., and Hoffman, B.J. Gene, 25, 263-269 (1983).

18 Loenen, W.A.M. and Brammar, W.J. Gene, 10, 249-259 (1980).

~341523 19 Fujiyama, A. et al. Nuc. Acids Res., 11, 4601-4610 (1983).
20 Gallo, R.C. et al. Proc Natl. Acad. Sci. USA, 79, 5680-5683 (1982).
21 Seiki, M., Hattori, S., Hirayama, Y. and Yoshida, M. Proc. Nati. Acad.
Sci. USA, 80, 3618-3622 (1983).
22 Haseltine, W.A. et a!. Science, 225, 419-421 (1984).
23 Sodroski, J. et al. Science, 225, 421-424 (1984).

Chen, I.S.Y, Mc Laughlin, J., Gasson, 3.C., Clark, S.C. and Golde, D.W.
Nature, 305, 502-505 (1983).

26 Shaw, G.M. et al. Proc. Nat1. Acad. Sci. USA, 81, 4544-4548 (1984).

27 Gelmann, E.P., Franchini, G., Manzari, V., Wong-Staal, F. and Gallo, R.C. Proc. Natl. Acad. Sci. USA, 81, 993-997 (1984).

23 Arya, S.K. et al. Science, 225, 927-930 (1984).
29 Harris, J.D. et al. Virology, 113, 573-583 (1981).

Steele, P.E., Rabscn, A.B., Bryan, T. and Martin, M.A. Science, 225, 943-947 (1984).

31 Montagnier, L. et al. Ann. Virol. (Institut Pasteur), 135 E, 119-134 (1984).

32 Lenz, J. et al. Nature, 308, 467-470 (1984).

33 Chen, I.S.Y., Mc Laughlin, J. and Goide, D.W. Nature, 309, 276-279 (1984).

34 Soberon, X., Covarrubias, L. and Bolivar, F. Gene, 9, 287-305 (1980).
Grunstein, M. and Hognhess, D. Proc. Natl. Acad. Sci. USA, 72, 3961-3965 (1975).

36 Sanger, F., Nicklen, S. and Coulsen, A.R. Proc. Natl. Acad. Sci. USA, 79, 5463-5476 (1977).

- ~ .

21 ~ 3 4~ 5 2 3 37 Southern, E.M. J. Mol. Biol., 98, 503-517 (1975).

38 Ish-Horowicz, D. and Burke, J.F. Nucl. Acids Res., 9, 2989-2998 (1981).

39 Benton, W.D. and Davis, R.W. Science, 196, 180-182 (1977).

Claims (32)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A DNA molecule which contains a cDNA sequence of a LAV virus sequence shown in Figures 4 to 11 or a cDNA sequence that is complemetary to the sequence shown in Figures 4 to 11 or a fragment of cDNA sequence, wherein said fragment is characterized by at least one of the following restriction sites:

Restriction Site ~~~Nucleotide position Hind III ~~~~~~0 Sac I ~~~~~~50 Bam HI ~~~~~~460 Hind III ~~~~~~520 Bam HI ~~~~~~600 Pst I ~~~~~~800 Hind III ~~~~~~1,100 Bgl II ~~~~~~1,500 Kpn I ~~~~~~3,500 Kpn I ~~~~~~3,900 Eco RI ~~~~~~4,100 Eco RI ~~~~~~5,300 Sal I ~~~~~~5,500 Kpn I ~~~~~~6,100 Bgl II ~~~~~~6,500 Bgl II ~~~~~~7,600 Hind III ~~~~~~7,850 Bam HI ~~~~~~8,150 Xho I ~~8,600 Kpn I ~~8,700 Bgl I ~~8,750 Bgl II ~~9,150 Sac I ~~9,200 Hind III ~~9,250.
2. The DNA molecule of claim 1, which is contained in a cloning vector.
3. The DNA molecule of claim 1, which contains the following restriction sites in the following order (from the 3 end to the 5' end):

Hind III, Sac I, Bgl II at the nucleotide position as shown in Figure 1 (LAV 75).
4. The DNA molecule of claim 3, which contains the following restriction sites in the following order:

Hind III, Sac I, Bgl II, Bgl II, Kpn I, at the nucleotide position as shown in Figure 1(LAV 82).
5. The DNA molecule of claim 3, which contains the following restriction sites in the following order:

Hind III, Sac I, Bgl II, Bgl II, Kpn I, Xho I, Bam HI, Hind III, Bgl II
at the nucleotide position as shown in Figure 1(LAV 13).
6. The DNA molecule of claim 5, which has a size of about 2.5 kb.
7. The DNA molecule of any one of claims 1, 3, 4, 5 or 6, which contains a region corresponding to the R and U3 regions of the LTR as well as the 3' end of the coding region of the LAV retroviral cDNA.
8. The DNA molecule of claim 1, which has a size from about 9.1 to 9.2 kb.
9. The DNA molecule of claim 8, which contains the following series of restriction sites:

Restriction Site ~Nucleotide position Hind III ~~~~0 Sac I ~~~~50 Bam HI ~~~~460 Hind III ~520 Bam HI ~600 Pst I ~800 Hind III ~1,100 Bgl II ~1,500 Kpn I ~3,500 Kpn I ~3,900 Eco RI ~4,100 Eco RI ~5,300 Sal I ~5,500 Kpn I ~6,100 Bgl II ~6,500 Bgl II ~7,600 Hind III ~7,850 Bam HI ~8,150 Xho I ~8,600 Kpn I ~8,700 Bgl I ~8,750 Bgl II ~9,150 Sac I ~9,200 Hind III 9,250.
10. The DNA molecule of claim 9, which contains an additional Hind III
site approximately at the nucleotide position 5, 550.
11. A DNA fragment as defined in claim 1, which comprises a sequence extending from approximately Kpn I site (6,100) to approximately Bam HI
site (8,150) of the sequence shown in Figures 4 to 11.
12. A DNA fragment as defined in claim 1, which comprises a sequence extending from approximately Kpn I site (3,500) to approximately Bgl II site (6,500) of the sequence shown in Figures 4 to 11.
13.A DNA fragment as defined in claim 1, which comprises a sequence extending from approximately Pst I site (800) to approximately Kpn I site (3,500) of the sequence shown in Figures 4 to 11.
14. A probe for the in vitro detection of LAV which consists of a nucleotide sequence that hybridizes to the sequence shown in Figures 4 to 11 under conditions of high stringency or a nucleotide sequence that hybridizes to a fragment under conditions of high stringency, wherein said fragment is characterized by at least one of the following restriction sites Restriction Site Nucleotide position Hind III ~0 Sac I ~50 Bam HI ~460 Hind III ~520 Bam HI ~600 Pst I ~800 Hind III ~1,100 Bgl II ~1,500 Kpn I ~3,500 Kpn I ~3,900 Eco RI ~4,100 Eco RI ~5,300 Sal I ~5,500 Kpn I ~6,100 Bgl II ~6,500 Bgl II ~7,600 Hind III ~7,850 Bam H I ~8,150 Xho I ~8,600 Kpn I ~8,700 Bgl I ~8,750 Bgl II~9,150 Sac I ~9,200 Hind III ~9,250.
15.A method for the in vitro detection of a viral infection due to LAV viruses which comprises contacting a biological sample originating from a person to be diagnosed tor LAV infection and containing DNA in a form suitable for hybridization with a probe specific for LAV DNA under highly stringent hybridizing conditions and detecting the hybridized probe.
16. A recombinant expression vector for the transformation of prokaryotic or eukaryotic cells, which contains, inserted in an expression vector, a DNA or a DNA fragment as defined in claim 1.
17. A recombinant expression vector for the transformation of prokaryotic or eukaryotic cells, which contains, inserted in an expression vector, the DNA
fragment of claim 11.
18. The vector of claim 16, which is a plasmid.
19.A microorganism, eukaryotic or prokaryotic cell, which is transformed by a recombinant expression vector according to claim 16 and which expresses the polypeptide encoded by the corresponding DNA fragment.
20. The polypeptide encoded by the DNA of claim 1 and expressed by the microorganisms of claim 19
21. A purified RNA of LAV viruses which has sizes from 9.1 to 9.2 kb and which hybridizes with the DNA molecule as defined in any one of claims 1 to 13 under high stringency conditions.
22. An RNA comprising LAV nucleotidic sequences and obtainable by transcription of or back synthesis from a cloned DNA which contains a DNA insertion fragment being all or part of a cDNA of a LAV retroviral genome contained in lambdaJ19 (CNCM 1-338) of LAV, wherein said DNA hybridizes under non stringent conditions with the genomic RNA of the LAV virus, but does not cross-hybridize with RNAs of HTLV-I and HTLV-II retroviruses in a dot-blot hybridization assay under low stringency conditions.
23. The RNA according to Claim 22, wherein said non stringent conditions are 20%
formamide, 8 × SSC and 37°C and washing under 2 × SSC, 0.1%
SDS and 37°C.
24. The RNA according to Claim 22, wherein said low stringency conditions are 20% formamide, 5 × SSC, 1 × Denhardt's solution, 10% Dextran sulphate at 37°C.
25. A kit for detecting LAV comprising a biological sample containing the RNA
according to any one of Claims 22 to 24.
26. A kit for detecting LAV comprising an RNA according to any one of claims 22 to 24.
27. A DNA in which a DNA insert comprises a sequence extending from KpnI
(6,100) to PvuII (8,500).
28. A DNA in which a DNA insert comprises a sequence extending from KpnI
(3,500) to PvuII (6,500).
29. A DNA in which a DNA insert comprises a sequence extending from PstI (800) to PvuII (3,800).
30. A DNA which contains a DNA insert being a LAV retroviral genome contained in .lambda..J19 (C.N.C.M. 1-338).
31. A DNA hybridizing under stringent conditions to the DNA insert according to Claim 30.
32. The DNA according to Claim 31, wherein said stringent conditions are 40%
formamide, 5 × SSC, 1 × Dernhardts solution, 10% Dextran at 37°C.
CA000491128A 1984-09-19 1985-09-19 Cloned dna sequences, hybridizable with genomic rna of lymphadenopathy-associated virus (lav) Expired - Lifetime CA1341523C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000491128A CA1341523C (en) 1984-09-19 1985-09-19 Cloned dna sequences, hybridizable with genomic rna of lymphadenopathy-associated virus (lav)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB84.23659 1984-09-19
CA000491128A CA1341523C (en) 1984-09-19 1985-09-19 Cloned dna sequences, hybridizable with genomic rna of lymphadenopathy-associated virus (lav)

Publications (1)

Publication Number Publication Date
CA1341523C true CA1341523C (en) 2007-03-27

Family

ID=37905020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000491128A Expired - Lifetime CA1341523C (en) 1984-09-19 1985-09-19 Cloned dna sequences, hybridizable with genomic rna of lymphadenopathy-associated virus (lav)

Country Status (1)

Country Link
CA (1) CA1341523C (en)

Similar Documents

Publication Publication Date Title
AU651952B2 (en) Cloned DNA sequences, hybridizable with genomic RNA of lymphadenopathy-associated virus (LAV)
Alizon et al. Molecular cloning of lymphadenopathy-associated virus
US5545726A (en) Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
AU580094B2 (en) Molecular clones of the genome of htlv-iii
EP0518443B1 (en) Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US7078516B1 (en) Nucleotide sequences derived from the genome of retroviruses of the hiv-1, hiv-2 and siv type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
USRE37918E1 (en) Nucleic acid derivatives
US5079342A (en) Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
US6054565A (en) Nucleic Acids of HIV-2, Diagnostic Test Kit and Method using Nucleic Acid Probes of HIV-2
US5770703A (en) Nucleic acids encoding peptides of the envelope region of HIV-2 and peptides, polypeptides, and methods for producing the peptides and polypeptides of the HIV-2 envelope gene
Josephs et al. Long terminal repeat structure of an American isolate of type I human T-cell leukemia virus
Leib-Mösch et al. Isolation of an SSAV-related endogenous sequence from human DNA
Campbell et al. Extensive envelope heterogeneity of simian immunodeficiency virus in tissues from infected macaques
Buonaguro et al. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program
Chiu et al. Molecular cloning of the unintegrated squirrel monkey retrovirus genome: organization and distribution of related sequences in primate DNAs
CA1341523C (en) Cloned dna sequences, hybridizable with genomic rna of lymphadenopathy-associated virus (lav)
Bosselman et al. Genome organization of retroviruses. VI. Heteroduplex analysis of ecotropic and xenotropic sequences of Moloney mink cell focus-inducing viral RNA obtained from either a cloned isolate or a thymoma cell line
US20030186219A1 (en) Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
USRE39282E1 (en) Nucleic acid derivatives
Callahan et al. A New Class of Human Endogenous Retroviral Genes

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20240327